3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
6
Lymphoma, Mantle-Cell
5
Waldenstrom Macroglobulinemia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Burkitt Lymphoma
1
Interventions
immunotoxin HA22
3
Cyclophosphamide
2
trametinib
1
polatuzumab vedotin
1
pembrolizumab
1
ontuxizumab
1
ibrutinib
1
fludarabine
1
dabrafenib
1
brexucabtagene autoleucel
1
acalabrutinib
1
Trazodone
1
Rituximab
1
Prednisone
1
PLX8394
1
Lenalidomide
1
HA 22
1
Fentanyl
1
Doxorubicin
1
AGS67E
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Hairy Cell
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts